Oncology Division

Ramaswamy Govindan, MD

Department of Medicine
Oncology Division
Medical Oncology

Research Interests

  • Lung cancer
  • Cancer genomics


  • 314-362-5737 (tel)
  • 314-747-7405 (secretary)
  • 314-362-3895 (fax)
  • 11th Floor Mid-Campus Center (office)
  • Division of Oncology
    Campus Box 8056
    Washington University Medical School
    660 South Euclid Avenue
    St. Louis, MO 63110


As a medical oncologist interested in thoracic malignancies, I have led a number of institutional and multi- center phase II and III studies in lung cancer over the past decade. Working with The McDonnell Genome Institute at the Washington University School of Medicine and with The Cancer Genome Atlas (TCGA) project (as a co-chair) sponsored by the NCI, I am actively involved in sequencing the whole genomes and exomes of several hundred patients with lung cancer. In addition, I am leading the efforts to move personalized therapies in early stage and locally advanced lung cancer. I am the Principal Investigator for the NCI funded large phase III randomized ALCHEMIST trial to study the role of erlotinib in patients with early stage EGFR mutated lung cancer. We have recently reported for the first-time mechanistic basis for acquired resistance to chemotherapy in patients with relapsed small cell lung cancer using whole exome and transcriptome sequencing. I am the Principal Investigator for the NCI funded consortium for the development of patient-derived xenograft (PDX) models to translate rapidly discoveries from bench to bedside. I have led Team Science effort through U01/U54 funded projects and the TCGA.